a statistical trendp = 0.094
For Stage II SCLC, PCI was associated with an overall survival benefit on multivariable analysis (HR 0.54, p = 0.047), as well as a statistical trend toward reduction in brain metastases (22.4 vs. 12.8%, p = 0.094).
For Stage II SCLC, PCI was associated with an overall survival benefit on multivariable analysis (HR 0.54, p = 0.047), as well as a statistical trend toward reduction in brain metastases (22.4 vs. 12.8%, p = 0.094).